📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Bafna Pharma Q3 FY26 Net Profit Rises 94% YoY to ₹1.84 Cr; Revenue Up 15%
Bafna Pharmaceuticals reported a steady year-on-year performance for Q3 FY26, with revenue from operations growing 15.4% to ₹38.29 crore. Net profit nearly doubled YoY to ₹1.84 crore, although it saw a sequential decline from ₹3.12 crore in Q2 FY26. The company is currently navigating significant regulatory hurdles, including GST demands totaling approximately ₹5.66 crore and overdue foreign currency receivables of ₹2.05 crore. Despite these challenges, the nine-month profit before tax has improved significantly to ₹5.31 crore from ₹2.84 crore in the previous year.
Key Highlights
Revenue from operations grew 15.4% YoY to ₹38.29 crore in Q3 FY26.
Net Profit for the quarter stood at ₹1.84 crore, up 93.8% from ₹0.95 crore in Q3 FY25.
Nine-month Profit Before Tax (PBT) surged to ₹5.31 crore compared to ₹2.84 crore in the prior year period.
Contingent liabilities include GST demands of ₹235.47 lakhs and ₹331.09 lakhs currently under appeal.
Foreign currency receivables of ₹2.05 crore are outstanding beyond RBI-stipulated timelines, requiring extension approvals.
💼 Action for Investors
Investors should monitor the outcome of the GST appeals as the total demand of over ₹5.6 crore is substantial compared to annual profits. While operational growth is positive, the sequential margin compression and regulatory 'Emphasis of Matter' by auditors warrant a cautious approach.
Bafna Pharma Credit Outlook Upgraded to Positive by ICRA; Reaffirms BB+ Rating
ICRA Limited has revised the credit outlook for Bafna Pharmaceuticals Limited from 'Stable' to 'Positive' while reaffirming its long-term rating at [ICRA] BB+. The rating applies to bank loan facilities totaling ₹50.00 crores, which include term loans of ₹25.87 crores and cash credit of ₹20.00 crores. Additionally, the short-term rating for non-fund-based facilities has been reaffirmed at [ICRA] A4+. This positive outlook indicates an expectation of improved financial stability and debt-servicing capability in the future.
Key Highlights
Outlook revised from 'Stable' to 'Positive' for ₹50.00 crore total bank facilities.
Long-term rating reaffirmed at [ICRA] BB+ for ₹25.87 crore term loans and ₹20.00 crore cash credit.
Short-term rating for Letter of Credit facilities reaffirmed at [ICRA] A4+.
The revision reflects ICRA's assessment of an improving credit profile for the pharmaceutical firm.
💼 Action for Investors
The outlook upgrade is a positive signal regarding the company's creditworthiness and could lead to lower interest expenses. Investors should monitor if this leads to a formal rating upgrade in the next 12 months.